Document:

EX-10.2

 Exhibit 10.2 

Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is
not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 
 FIRST
AMENDMENT 
 TO 

EXCLUSIVE LICENSE AGREEMENT 
 This
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made and entered into as of February 12, 2019 (“Amendment Effective Date”) by and between Vor Biopharma Inc. (“Company”) and The Trustees of
Columbia University in the City of New York (“Columbia”). 
 W I T N E S S E T H: 

WHEREAS, Company and Columbia are parties to that certain Exclusive License Agreement dated April 28, 2016 (the “Agreement”). Each capitalized
term used herein, and not otherwise defined herein, shall have the meaning set forth in the Agreement; 
 WHEREAS, Company and the Columbia wish to amend
the Agreement in certain respects to add intellectual property licensed to Company under the Agreement; 
 NOW, THEREFORE, in consideration of the premises
and the mutual covenants herein set forth, the parties hereto hereby agree as follows: 
  

	1.	 Replacement of Exhibit A with Exhibit A-1 (Patents). Exhibit A
is hereby deleted in its entirety and replaced with Exhibit A-1 attached as Appendix 1 hereto. Each mention in the Agreement of “Exhibit A” will now be deemed to be a reference to “Exhibit A-1”. 

  

	2.	 Replacement of Exhibit B with Exhibit B-1 (Materials and Technical
Information). Exhibit B is hereby deleted in its entirety and replaced with Exhibit B-1 attached as Appendix 2 hereto. Each mention in the Agreement of “Exhibit B” will now be deemed to be a
reference to “Exhibit B-1”. 

  

	3.	 Section 1l is hereby deleted in its entirety and replaced with the following: 

“’Net Sales’ shall mean [***]: 

(i) [***]; 
 (ii) [***]; 

(iii) [***]; 
 (iv) [***]; 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 (v) [***]; 

[***] 
  

	4.	 Section 1s is hereby deleted in its entirety and replaced with the following: 

“ ‘Technical Information’ shall mean any know-how, technical information and data
developed by Columbia by or under the direction of [***] prior to the Amendment Effective Date and provided to or received by Company, which know-how, technical information and data are necessary or useful for
the discovery, development, manufacture, use, sale, offering for sale, importation, exportation, distribution, rental or lease of a Product, including, without limitation, (i) any know-how, technical
information and data disclosed in any Patent or (ii) any reports or disclosures concerning research or inventions provided or disclosed to, or otherwise received by, Company. Technical Information shall include, but is not limited to, the
information set forth in Exhibit B hereto.” 
  

	5.	 Section 4d is hereby deleted in its entirety and replaced with the following: 

“Sublicense Payments. In consideration of Company’s right to grant sublicenses under Section 2b, Company shall pay to
Columbia [***] of any Sublicense Income received by Company from Company’s Sublicensees. For purposes of this Section 4d, ‘Sublicense Income’ shall mean [***]. Notwithstanding the foregoing, Sublicense Income will [***].”

 Each mention in the Agreement of ‘Other Sublicensee Revenue’ will now be deemed to be a reference to ‘Sublicense
Income.’ 
  

	6.	 Section 4e shall be amended by adding the following language to the end of the provision: “In the
event a Developer develops a Subsequent Product for potential commercial sale in the Territory, Company shall pay to Columbia the nonrefundable, non-recoverable Developer Milestone Payments set forth in
Section 4e(iv) – (vi) with respect to the Subsequent Product to reach each milestone or when the milestone is first achieved by a Subsequent Product, as applicable. “Subsequent Product” as used in this Section 4(e)
means a Product that (i) is Covered by a Valid Claim of a Patent resulting from [***] or (ii) uses or incorporates any information, data or subject matter disclosed in any patent application resulting from [***], to the extent that such
information, data or subject matter is not specifically or expressly disclosed in any patent application resulting from [***]. The Parties agree that the disclosure of a genus in a patent application resulting from [***] does not constitute a
specific or express disclosure of a species within said genus. 

 The Parties agree that if a Subsequent Product is the
first Product to achieve the milestones set forth in Section 4e(i) – (vi), the Company shall pay to Columbia the non-refundable, non-recoverable Developer
Milestone Payments corresponding to such milestones. No further Developer Milestone Payments shall be due for any Product that subsequently achieves the milestones set forth in Section 4e(i) – (iii);

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 however, Company will still pay to Columbia the Developer Milestone
Payments for a second Product that achieves the milestones set forth in Section 4e(iv) – (vi), provided that such second Product is a Subsequent Product. Notwithstanding the foregoing, Company shall not be obligated to pay to Columbia the
Developer Milestone Payments set forth in Section 4e(iv) – (vi) more than twice.” 
  

	7.	 Section 6a shall be amended by adding the following language after subsection (i): 

“ii. Conduct good faith due diligence on opportunities to develop and commercialize Products that (i) use or incorporate any
information, data, or subject matter disclosed in [***] or disclosed in any patent application resulting from [***] or (ii) are Covered by a Valid Claim of a Patent resulting from [***] which diligence shall include but is not limited to
[***].” 
  

	8.	 Section 18 is hereby deleted in its entirety and replaced with the following: 

“Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations under this Agreement without the
prior written consent of the other Party, except that Company may make such an assignment or transfer without Columbia’s consent (a) to Company’s Affiliates or (b) to the successor to all or substantially all of the business or
assets of Company to which this Agreement relates (whether by merger, sale of stock, sale of assets or other transaction). Company will provide notice to Columbia of such assignment within [***]. Any permitted assignment will be binding on the
successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 18 will be null and void.” 
  

	9.	 Except as expressly set forth in this Amendment, the Agreement shall remain in full force and effect. If there
is any inconsistency or conflict between this Amendment and the Agreement, the provisions of this Amendment shall govern and control. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. This Amendment shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to Agreement to be
executed as of the date first above written. 
  

	
	 THE TRUSTEES OF COLUMBIA

UNIVERSITY IN THE CITY OF NEW YORK

	
	By /s/ Orin Herskowitz
	Name: Orin Herskowitz
	Title: Executive Director, CTV
	TTS: [***]
	
	VOR BIOPHARMA INC.
	
	By /s/ Bharatt Chowrira
	Name: Bharatt Chowrira
	Title: Chief Executive OfficerEX-10.3

 Exhibit 10.3 

Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted
information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT – EXCLUSIVE 

This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service
(“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug
Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Vor Biopharma, Inc. 

hereinafter referred to as the “Licensee”, 

having offices at 100 Cambridgepark Dr, Suite 400, Cambridge, Massachusetts 02140 

created and operating under the laws of Delaware. 

Tax ID No.: 81-1591163 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 For the IC internal use only: 

License Number: 
 License
Application Number: A-273-2020 
 Serial Number(s) of
Licensed Patent(s) or Patent Application(s): 
 [***] 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Additional Remarks: 
 Public
Benefit(s): 
 The public interest would be well served by an exclusive license for this technology since therapies are needed for the
treatment of CD33 expressing cancers, among which are AML with a mortality rate of 10,000 per year and five-year survival of only 25%. AML is a rare disease and as a pediatric indication has inherent challenges in the development of new therapies.

 This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a
Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty
Report), and Appendix G (Royalty Payment Options). 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 The IC and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the IC investigators made inventions
that may have commercial applicability. 

  

	 	1.2	 By assignment of rights from IC employees and other inventors, HHS, on behalf of the
Government, owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assigned inventions. HHS also owns any tangible embodiments of these inventions actually reduced
to practice by the IC. 

  

	 	1.3	 The Secretary of HHS has delegated to the IC the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The IC desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Additional License” means an exclusive, co-exclusive
or non-exclusive commercial license that includes the Licensed Patent Rights and is granted by the IC to a Third Party (“Additional Licensee”). For clarity,
any Research License granted under the Licensed Patent Rights that does not require the Third Party licensee to pay a share of patent expenses shall not be deemed an “Additional License”.

  

	 	2.2	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation
or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.3	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.4	 “Combination Product” means a Licensed Product(s) that contains a Licensed
Product(s) and at least one Non-Licensed Product. [***]. 

  

	 	2.5	 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

  

	 	2.6	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.7	 “Fair Market Value” means the total amount or value expressed in U.S. dollars obtained by the
Licensee through the transfer or sale of its assets. 

  

	 	2.8	 “FDA” means the Food and Drug Administration. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	2.9	 “First Commercial Sale” means the initial transfer by or on behalf of the Licensee or
its Sublicensees of the Licensed Products or the initial practice of a Licensed Process by or on behalf of the Licensee or its Sublicensees in exchange for cash or some equivalent to which value can be assigned for
the purpose of determining Net Sales. 

  

	 	2.10	 “Government” means the Government of the United States of America. 

 

	 	2.11	 “IC Auto Product” means a Licensed Product that is within the scope of the Licensed
Fields of Use I (1) in Appendix B. 

  

	 	2.12	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.13	 “Licensed Materials” means [***]. 

 

	 	2.14	 “Licensed Patent Rights” shall mean: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): 

  

	 	(i)	 continuations-in-part of
2.14(a); 

  

	 	(ii)	 all divisions and continuations of these
continuations-in-part; 

  

	 	(iii)	 all patents issuing from these
continuations-in-part, divisions, and continuations; 

  

	 	(iv)	 priority patent application(s) of 2.14(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in 2.14(a): all counterpart foreign and U.S. patent applications and patents to 2.14(a) and 2.14(b), including those listed in Appendix A; and 

  

	 	(d)	 Licensed Patent Rights shall not include
2.14(b)(i)-2.14(b)(iii) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.14(a). 

 

	 	2.15	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more claims of the Licensed Patent Rights, in the country of practice, that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

  

	 	2.16	 “Licensed Products” means tangible materials, the manufacture, use, sale, or importation of
which would, but for the license granted to the Licensee in this Agreement, infringe one or more Valid Claims of the Licensed Patent Rights, in the country of sale. 

 

	 	2.17	 “Licensed Territory” means the geographical area identified in Appendix B.

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	2.18	 “Major Asia-Pacific Country” means [***]. 

 

	 	2.19	 “Major European Country” means [***]. 

 

	 	2.20	 “Net Sales” means the total gross receipts for sales of Licensed Products or practice
of Licensed Processes by or on behalf of the Licensee or its Affiliates or Sublicensees, and from leasing, renting, or otherwise making the Licensed Products available to others without sale or other dispositions,
whether invoiced or not, less [***]. With respect to Combination Products, the following shall apply: 

  

	 	(a)	 In the event that a Licensed Product is sold as a Combination Product, Net Sales of the
Combination Product will be calculated by [***]. 

  

	 	(b)	 In the event that: (a) the Licensed Product without the
Non-Licensed Product(s) is sold separately in the same formulation and dosage during the applicable calendar quarter; and (b) the Non-Licensed
Product(s) in the same formulation and dosage as in the Combination Product are not sold separately during the applicable calendar quarter, then Net Sales of the Combination Product will be calculated by [***].

  

	 	(c)	 In the event that, in a particular country: (a) the Licensed Product without the Non-Licensed Product(s) is not sold separately in the same formulation and dosage during the applicable calendar quarter; and (b) the Non-Licensed Product(s)
in the same formulation and dosage as in the Combination Product are not sold separately during the applicable calendar quarter, the adjustment to Net Sales shall be determined by [***]. 

[***] 
  

	 	2.21	 “Non-Licensed Product” means an active therapeutic
component or device other than a Licensed Product that is included in a Combination Product and that is not covered by the Licensed Patent Rights. 

 

	 	2.22	 “Phase 1 Clinical Trial” means a study in humans which provides for the first introduction
into humans of a Licensed Product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21
C.F.R. §312.21(a) or its foreign equivalents. 

  

	 	2.23	 “Phase 2 Clinical Trial” means a study in humans of the safety, dose ranging and efficacy of a
Licensed Product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase 3 Clinical Trial or to file for accelerated approval, or otherwise consistent with the requirements of U.S. 21 C.F.R.
§312.21(b) or its foreign equivalents. 

  

	 	2.24	 “Phase 3 Clinical Trial” means a controlled study in humans of the efficacy and safety of a
Licensed Product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient to file for marketing authorization, or otherwise consistent
with the requirements of U.S. 21 C.F.R. §312.21(c) or its foreign equivalents. 

  

	 	2.25	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	2.26	 “Pro Rata Share” means one of the following: 

 

	 	(a)	 in instances where the Additional License(s) granted by IC recover a pre-determined percentage of patent costs, [***]; 

  

	 	(b)	 in instances where the Additional Licenses granted by IC recover a full pro rata share of patent
prosecution costs, [***]; or 

  

	 	(c)	 in instances where the Additional Licenses are granted according to the definition of both
2.26(a) and 2.26(b), [***]. 

  

	 	2.27	 “Priority Review” means, with respect to a human drug application as defined in section 735(1)
[21 USC § 379g(1)], review and action by the Secretary of HHS (“Secretary”) on such application not later than six (6) months after receipt by the Secretary of such application, as described in the Manual of
Policies and Procedures of the FDA and goals identified in the letters described in section 101(b) of the Prescription Drug User Fee Amendments of 2012. 

 

	 	2.28	 “Priority Review Voucher” means a voucher issued by the Secretary to the
Licensee for a rare pediatric disease product application that entitles Licensee or Licensee’s transferee of such voucher to Priority Review of a human drug application submitted under section 505(b)(1) [21 USC
§ 355(b)(1)] or section 351(a) of the Public Health Service Act [42 USC § 262] after the date of approval of the rare pediatric disease product application. For the purposes of this Agreement, Priority Review Voucher refers
to any such voucher that the Licensee obtains as a result of its activities that relied upon Licensed Products or Licensed Processes. 

  

	 	2.29	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	 	2.30	 “Stem Cell Transplant” means replacement of a patient’s hematopoietic stem cells with a
transplanted hematopoietic stem cell product, which may be unmanipulated, enriched, and/or engineered. For the avoidance of doubt, Stem Cell Transplant is not a CAR-T derived from an apheresis product
containing a hematopoietic stem cell population. 

  

	 	2.31	 “Sublicensee” means a Third Party to whom Licensee has granted or authorized a
sublicense under the Licensed Patent Rights pursuant to Section 4.1 hereunder. For clarity, a Third Party Subcontractor is not a Sublicensee. 

 

	 	2.32	 “Sublicensing Revenue” means the Fair Market Value of any consideration actually
received by Licensee from a Sublicensee as consideration for the grant of rights to such Sublicensee under the Licensed Patent Rights that include the right to manufacture and commercialize a Licensed Product.
Sublicensing Revenue includes upfront fees, license maintenance fees, and milestone payments, and other payments received by Licensee in consideration for any such rights granted to Licensed Patent Rights under a sublicense
agreement, but excludes [***]. Any dispute between the parties related to the allocation of Sublicensing Revenue will be resolved in accordance with Article 14. 

 

	 	2.33	 “Third Party” means a person or entity other than (i) Licensee or any of its
Affiliates and (ii) IC. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	2.34	 “Third Party Contractor(s)” means a Third Party organization providing contract
research, development, manufacturing, or medical services (for example, CRO, CDO, CMO), that is acting with, on behalf and for the benefit of Licensee, for consideration provided by the Licensee on a fee-for-service basis to perform services or provide materials specified by the Licensee. 

 

	 	2.35	 “Valid Claim” shall mean a patent claim within either an issued patent or a pending patent
application within the Licensed Patent Rights, in each case that has not been abandoned, lapsed or disclaimed or held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction and,
in the case of any such claim of a pending patent application, wherein such claim has not been pending for greater than [***] from the date of the first official office action on the merits for such patent application in the relevant jurisdiction.
In the event that any pending claim within a pending patent application within the Licensed Patent Rights ultimately issues after having been pending for greater than such [***] period, such issued claim shall be deemed to have been a
Valid Claim during the period prior to and after such [***] period after its issuance. 

  

	 	2.36	 “Vor Allo Product” means a Licensed Product that is within the scope of the Licensed
Fields of Use I (2) in Appendix B. 

  

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The IC hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. 

  

	 	3.2	 The IC hereby grants to the Licensee a
non-exclusive license to make, have made, use, but not to sell the Licensed Materials, and to research, develop, make, have made, use and have used, sell and have sold, and import
the Licensed Products. The Licensee is entitled to authorize its Third Party Contractor(s) to research, develop, make, have made, use, and provide Licensee with, but not to provide or sell
Licensed Materials and Licensed Products to Third Parties, except to the extent that such Third Parties are working on Licensee’s behalf. For the avoidance of doubt, Licensee
shall be allowed to pay Third Party Contractor(s) for the provision of Licensed Materials, Licensed Products, or related services to Licensee. Licensee shall ensure that such Third Party
Contractor(s) comply with the applicable terms and obligations of this Agreement with respect to the use of the Licensed Materials and the Licensed Products. 

 

	 	3.3	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the IC other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which
shall not be unreasonably withheld, the Licensee may enter into agreements granting and authorizing sublicenses under the Licensed Patent Rights; provided that if the IC does not provide a response within [***] of its receiving
such sublicense agreement, then the IC shall be deemed to have consented to such sublicense agreement. The Licensee may also exercise its rights and fulfill its obligations hereunder through one or more Affiliates, provided that
Licensee shall be and remain responsible for the acts or omissions of its Affiliates hereunder. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	4.2	 The Licensee agrees that any sublicenses granted by it under the Licensed Patent Rights to
Sublicensees shall provide that obligations corresponding to the obligations of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement
shall be binding upon the Sublicensee. The Licensee further agrees to attach copies of the obligations corresponding to these Paragraphs to (or otherwise include them in) all sublicense agreements. 

 

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the Sublicensees and the IC, at the option of the Sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to IC approval, which
shall not be unreasonably withheld or delayed, contingent upon acceptance by the Sublicensee of the remaining provisions of this Agreement. 

  

	 	4.4	 The Licensee agrees to forward to the IC a complete copy of each fully executed agreement
granting a sublicense under the Licensed Patent Rights, postmarked within [***] of the execution of the agreement. To the extent permitted by law, the IC agrees to maintain each sublicense agreement in confidence.

  

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	 	5.1	 

  

	 	(a)	 the IC reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or
international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. Prior to the First Commercial Sale, the Licensee agrees to provide the IC with reasonable
quantities of the Licensed Products or materials made through the Licensed Processes for IC research use; and 

  

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have
the Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that
is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial
Sale, the Licensee agrees to provide the IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC research use. 

 

	 	5.2	 The Licensee agrees that products used or sold in the United States embodying the Licensed
Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC. 

 

	 	5.3	 The Licensee acknowledges that the IC may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the IC when acquiring
these rights is necessary in order to make a CRADA project feasible. The Licensee may request an opportunity to join as a party to the proposed CRADA. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(a)	 in addition to the reserved license of Paragraph 5.1, the IC reserves the right to grant Research
Licenses directly or to require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In
order to safeguard the Licensed Patent Rights, however, the IC shall consult with the Licensee before granting to commercial entities a Research License or providing to them research samples of materials made through the
Licensed Processes and shall consider Licensee’s comments in good faith, especially as it relates to the commercialization of a Licensed Product; and 

 

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to
use the Licensed Patent Rights in the Licensed Fields of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license
itself. The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; or 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the IC a nonrefundable minimum annual royalty as set forth in Appendix
C. 

  

	 	6.3	 The Licensee agrees to pay the IC earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the IC benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the IC sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent claim within any patent or patent application licensed under this Agreement shall cease to be a
Valid Claim within the Licensed Patent Rights for the purpose of computing royalty payments in any given country on the earliest of the dates that: 

 

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses; 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency; or 

  

	 	(d)	 the patent application has been pending for more than [***] from the date of the first official office action
on the merits for such patent application in the relevant jurisdiction. 

  

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of the Licensed Products by the Licensee made in other than an arm’s-length transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an
arm’s-length transaction, based on sales of like quantity and quality products on or about the time of this transaction. 

 

	 	6.9	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive, co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a Pro Rata Share of patent expenses for
the Licensed Patent Rights that are paid by the IC or the Licensee prior to the effective date of the relevant Additional License, pursuant to similar terms to those set forth for Licensee hereunder. With regard to
expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed Patent Rights and paid by the IC prior to the effective date of this Agreement,
the Licensee shall pay the IC, as an additional royalty, an amount equivalent the expenses previously paid by the IC prior to the effective date of this Agreement as follows: 

 

	 	(a)	 A first amount equivalent to [***] of the unreimbursed patent expenses due under this paragraph 6.9 will be
paid no later than [***]; 

  

	 	(b)	 A second amount equivalent to [***] of the unreimbursed patent expenses due under this paragraph 6.9 will be
paid no later than the first to occur of [***]; 

  

	 	(c)	 A third amount equivalent to [***] of the unreimbursed patent expenses due under this paragraph 6.9 will be
paid no later than the first to occur of [***]. 

  

	 	6.10	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive, co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a Pro Rata Share of patent expenses for
the Licensed Patent Rights that are paid by the IC and/or Licensee on or after to the effective date of the relevant Additional License, pursuant to similar terms to those set forth for Licensee hereunder.
With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed Patent Rights and paid by the IC on or after the effective
date of this Agreement, the IC, at its sole option, may require the Licensee: 

  

	 	(a)	 to pay the IC on an annual basis, within [***] of the IC’s submission of a statement and
request for payment, a royalty amount equivalent to the Pro Rata Share of these unreimbursed expenses paid during the previous calendar year(s); 

  

	 	(b)	 to pay the Pro Rata Share of these unreimbursed expenses directly to the law firm employed by the
IC to handle these functions. However, in this event, the IC and not the Licensee shall be the client of the law firm; or 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(c)	 in limited circumstances, the Licensee may be given the right to assume responsibility for the
preparation, filing, prosecution, or maintenance of any patent application or patent included with the Licensed Patent Rights. In that event, the Licensee shall directly pay the attorneys or agents engaged to prepare, file, prosecute,
or maintain these patent applications or patents and shall provide the IC with copies of each invoice associated with these services as well as documentation that these invoices have been paid. 

 

	 	6.11	 The IC agrees, upon written request, to provide the Licensee with summaries of patent prosecution
invoices for which the IC has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the IC related to patent prosecution costs shall be treated as
confidential commercial information and shall not be released to a Third Party except as necessary for Sublicensees and except as required by law or a court of competent jurisdiction. 

 

	 	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon [***] written notice to the IC and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after [***] of the effective date of the written notice. Upon
Licensee’s request in connection with such notice, the IC will discuss in good faith with Licensee whether such Licensed Patent Rights in such country should be abandoned, based on the collective interests of
Licensee, the IC and its Additional Licensees under such Licensed Patent Rights. 

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the IC agrees to take responsibility for, but to consult
in good faith with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall promptly furnish copies of relevant patent-related documents to the Licensee for review and comment, which comments the IC shall consider in good faith. The IC shall, subject to good faith consideration of comments from the
Licensee, select registered patent attorneys or patent agents to prepare, file, prosecute and maintain the Licensed Patent Rights on behalf of the IC. Without limiting the foregoing, IC shall provide Licensee with
a list of proposed filings (including which countries are being elected, validated or nationalized, and/or filing of continuations or divisionals), at least [***] prior to a filing deadline when practicable, for any and all patent applications or
patents included in the Licensed Patent Rights. If Licensee would like an additional filing or a filing in an additional country that is not listed, Licensee will submit such a request in writing to the IC within [***] of
receipt of the IC’s proposed filings. If the IC does not agree with the Licensee’s request and cannot provide the Licensee with a bona fide reason (including without limitation, claims are not patentable) why
the IC has elected not to comply with the Licensee’s request, then the Licensee may, at its own expense, assume the responsibility for the preparation, filing, prosecution, and maintenance of any and all such requested
patent applications or patents included in the Licensed Patent Rights and shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the IC. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	7.2	 Upon the IC’s written request or in the event that the IC elects to abandon or otherwise
cease the prosecution and maintenance of any Licensed Patent Rights (in which case the IC shall provide the Licensee with prompt written notice, not less than [***] in advance of any applicable filing deadline, when
practicable), the Licensee may assume the responsibility for the preparation, filing, prosecution, and maintenance of any and all applicable patent applications or patents included in the Licensed Patent Rights and shall, on an ongoing
basis, promptly furnish copies of all patent-related documents to the IC. In this event, the Licensee shall, subject to the prior approval of the IC, select registered patent attorneys or
patent agents to provide these services on behalf of the Licensee and the IC. The IC shall provide appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or patent agents
providing these services. The Licensee and its attorneys or agents shall consult with the IC in all aspects of the preparation, filing, prosecution and maintenance of patent applications and patents included within the Licensed
Patent Rights and shall provide the IC sufficient opportunity to comment on any document that the Licensee intends to file or to cause to be filed with the relevant intellectual property or patent office. 

 

	 	7.3	 At any time, the IC may provide the Licensee with written notice that the IC wishes to
reassume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. If the IC elects to reassume these responsibilities, the Licensee
agrees to cooperate fully with the IC, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and to provide the IC
with complete copies of any and all documents or other materials that the IC deems necessary to undertake such responsibilities. The Licensee shall be responsible for all costs associated with transferring patent prosecution
responsibilities to an attorney or agent of the IC’s choice. 

  

	 	7.4	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent
Rights, which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the IC. These records shall be retained for at [***] following a given reporting period and shall
be available during normal business hours for inspection, at the expense of the IC, by an accountant or other designated auditor selected by the IC for the sole purpose of verifying reports and royalty payments hereunder. The
accountant or auditor shall only disclose to the IC information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of [***] for any
[***] period, then the Licensee shall reimburse the IC for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments
required under this Paragraph shall be due within [***] of the date the IC provides to the Licensee notice of the payment due. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the IC with the Commercial
Development Plan in Appendix E, under which the Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated
by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for each of the Licensed Fields of Use within [***] after [***] of each calendar year. These progress reports shall include, but not be limited to: progress on research and
development, Third Party Contractor(s) to whom Licensed Materials have been provided, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding
calendar year, as well as, any material adjustments to Licensee’s plans for the present calendar year with respect to the Licensed Products. The IC also encourages these reports to include information on any of the
Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress materially differs from that projected in the Commercial Development Plan and Benchmarks, the Licensee shall
explain the reasons for these differences. In the annual report, or at other times, the Licensee may propose amendments to the Commercial Development Plan, acceptance of which by the IC may not be denied unreasonably. The
Licensee agrees to provide any additional information reasonably required by the IC to evaluate the Licensee’s performance under this Agreement. The Licensee may amend the Benchmarks at any time upon
written approval by the IC which shall not be unreasonably withheld, delayed, or conditioned. The IC shall not unreasonably withhold approval of any request of the Licensee to extend the time periods of this schedule if the
request is supported by a reasonable showing by the Licensee of diligence in its performance under the Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application as defined
in 37 C.F.R. §404.3(d). The Licensee shall amend the Commercial Development Plan and Benchmarks at the request of the IC to address any Licensed Fields of Use not specifically addressed in the plan
originally submitted. 

  

	 	9.3	 The Licensee shall report to the IC the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of Licensee’s knowledge of such occurrences. 

 

	 	9.4	 After the First Commercial Sale, the Licensee shall submit to the IC, within [***] after
each calendar half-year ending [***] and [***], a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount
of the Licensed Products sold or Licensed Processes practiced by or on behalf of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due to the
IC. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned royalties are due to the IC for any reporting period, the written report shall so state. The royalty report shall be certified
as correct by an authorized officer of the Licensee and shall include a total of all deductions made under Paragraph 2.20 to determine Net Sales made under Article 6 to determine royalties due. The royalty report shall also identify
the site of manufacture by Licensee (if applicable) for the Licensed Product(s) sold in the United States. 

  

	 	9.5	 The Licensee agrees to forward semi-annually to the IC a
copy of these reports received by the Licensee from its Sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the IC by the Licensee
for activities under the sublicense. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the IC at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income that
Licensee receives is owed inside or outside the United States and shall pay the tax and be responsible for all associated filings with appropriate agencies of domestic or foreign governments, provided that such tax shall be deductible from
the calculation of Net Sales as set forth in Paragraph 2.20. 

  

	 	9.8	 Additional royalties may be assessed by the IC on any payment that is more than [***] overdue at the
rate of [***] per month. This [***] per month rate may be applied retroactively from the original due date until the date of receipt by the IC of the overdue payment and additional royalties. The payment of any additional royalties shall not
prevent the IC from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the IC as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the IC under the Freedom of
Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

  

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include using reasonable commercial efforts to adhere to the Commercial Development Plan in Appendix
E and performance of the Benchmarks in Appendix D. The efforts of an Affiliate or Sublicensee hereunder shall be considered the efforts of the Licensee. 

 

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to use reasonable commercial efforts
to make reasonable quantities of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to use reasonable commercial efforts to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses
of the Licensed Products. 

  

	 	10.5	 At IC’s reasonable request and to the extent reasonably practicable, the Licensee agrees to
supply, to the Mailing Address for Agreement Notices indicated on the Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for
educational and display purposes only. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT  

 

	 	11.1	 The IC and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights, as well as, any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

 

	 	11.2	 Infringement in Licensed Fields of Use: 

 

	 	(a)	 For any infringement of the Licensed Patent Rights that falls within the Licensed Fields of Use,
the Licensee shall have the first right, but not the obligation, at the Licensee’s cost, to enforce and shall keep IC and any Additional Licensee(s) reasonably informed with respect thereto. 

 

	 	(b)	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, for any infringement in
the Licensed Fields of Use, the Licensee: 

  

	 	(i)	 shall have the right to bring suit in its own name, at its own expense, and on its own behalf for infringement
of presumably Valid Claims in the Licensed Patent Rights with respect to such infringement; 

  

	 	(ii)	 may in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; 

  

	 	(iii)	 may settle any claim or suit for infringement of the Licensed Patent Rights; provided, however, that the
IC and appropriate Government authorities shall have the right to review and approve (such approval not to be unreasonably withheld, conditioned or delayed) any such settlement that imposes any liability on the IC or any other
Government authority that is not subject to reimbursement by Licensee hereunder; and 

  

	 	(iv)	 if the Licensee desires to initiate such a suit for infringement of the Licensed Patent Rights in
the Licensed Fields of Use, the Licensee shall notify the IC in writing, and the Licensee shall be free to initiate and control such suit. The IC shall have a continuing right to consult, using counsel of its own
choice, in any enforcement action brought or controlled by the Licensee hereunder. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement, other than to the
extent required to enable the Licensee to enforce the Licensed Patent Rights in accordance with this Article 11. The Licensee may request the Government to initiate or join in any suit if necessary to avoid dismissal of
the suit, and the Government shall not unreasonably deny Licensee’s request. Should the Government be made a party to any suit brought by Licensee to enforce the Licensed Patent Rights, the Licensee
shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the motion or other action, including all costs incurred by the Government in opposing the motion or other action being
joined in such suit. In all cases, the Licensee agrees to keep the IC reasonably apprised of the status and progress of any such litigation. Before the Licensee commences an infringement action to enforce the Licensed Patent
Rights, the Licensee shall notify the IC and give careful consideration to the views of the IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(c)	 If the Licensee has elected not to take action with respect to infringement of the Licensed Patent
Rights in the Licensed Fields of Use within [***] of receiving or providing notice thereof pursuant to Paragraph 11.1, the IC shall have the right, but not the obligation, to assume, at its own expense, the responsibility for the
enforcement of such Licensed Patent Rights against such infringement, under the terms and conditions set forth in Paragraph 11.4(b), and shall keep the Licensee reasonably informed with respect thereto. 

 

	 	11.3	 Infringement outside the Licensed Fields of Use: 

 

	 	(a)	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, for any infringement of
the Licensed Patent Rights that is solely in fields outside the Licensed Fields of Use (“Unlicensed Fields of Use”), the Licensee may: 

 

	 	(i)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(ii)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(iii)	 settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that the
IC and appropriate Government authorities shall have the first right to take such actions; and 

  

	 	(iv)	 if the Licensee desires to initiate a suit for infringement of the Licensed Patent Rights in the
Unlicensed Fields of Use, the Licensee shall notify the IC in writing. If the IC does not notify the Licensee of its intent to pursue legal action within [***] of such notice, the Licensee shall be free to
initiate such suit. The IC shall have a continuing right to intervene in the suit. The Licensee shall take no action to compel the Government either to initiate or to join in any suit for patent infringement. The Licensee
may request the Government to initiate or join in any suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any suit, the Licensee shall reimburse the Government for any costs,
expenses, or fees which the Government incurs as a result of the motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, the Licensee agrees to keep the
IC reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the IC and give careful consideration to the views of the IC and
to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(v)	 if the IC desires to initiate a suit for infringement of the Licensed Patent Rights in the
Unlicensed Fields of Use, the IC shall notify the Licensee in writing, and the IC shall be free to inititate and control such suit. The Licensee shall have a continuing right to consult, using counsel of its own
choice, in any enforcement action brought or controlled by the IC hereunder. The IC shall take no action to compel the Licensee either to initiate or to join in any suit for patent infringement, other than to the extent required
to enable the IC to enforce the License Patent Rights in accordance with this Article 11. The IC may request the Licensee to initiate or join in any suit if necessary to avoid dismissal of the suit, and the
Licensee shall not unreasonably deny the IC’s request. In all cases, the IC agrees to keep the Licensee reasonably apprised of the status and progress of any litigation. Before the IC commences an infringement
action to enforce the Licensed Patent Rights, the IC shall notify the Licensee and give careful consideration to the views of the Licensee and to any potential effects of the litigation on the Licensee in deciding
whether to bring suit. 

  

	 	11.4	 In the event that a declaratory judgment action alleging invalidity or
non-infringement of any of the Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the
Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29 or other statutes, the Licensee may: 

 

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided,
however, that the IC and appropriate Government authorities shall have the first right to review and approve (such approval not to be unreasonably withheld, conditioned or delayed) any such settlement that imposes any liability on the
IC or any other Government authority that is not subject to reimbursement by Licensee hereunder or adversely impacts the Licensed Patent Rights; and 

 

	 	(d)	 if the IC does not notify the Licensee of its intent to respond to a declaratory judgment action
alleging invalidity or non-infringement of any of the Licensed Patent Rights brought against the IC within a reasonable time, not to exceed [***] from when such action is brought, the IC
shall notify the Licensee, and the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may
request the Government to initiate or to join any suit if necessary to avoid dismissal of the suit and the Government shall not unreasonably deny Licensee’s request. Should the Government be made a party to any suit
by motion or any other action brought by the Licensee, the Licensee shall reimburse the Government for any costs, expenses, or fees, which the Government incurs as a result of being joined in such suit. If the
Licensee elects not to defend against the declaratory judgment action, the IC, at its option, may do so at its own expense. In all cases, the party controlling such action agrees to keep the other party reasonably apprised of the
status and progress of any litigation. Before the Licensee commences such a defensive action with respect to the Licensed Patent Rights, the Licensee shall notify the IC and give careful consideration to the views of the
IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	11.5	 In any action under Paragraphs 11.2, 11.3, or 11.4, the expenses including costs, fees, attorney fees, and
disbursements, shall be paid by the party controlling such action or as otherwise set forth under such Paragraphs. From the value of any recovery made through court judgment or settlement of any such action, any remaining value of any such recovery
following reimbursement of Licensee’s and other parties’ litigation costs (“Recovery Margin”) shall be treated as follows: 

  

	 	(a)	 Recovery in Licensed Fields of Use: the Recovery Margin [***].

  

	 	(b)	 Recovery in Unlicensed Fields of Use: the Recovery Margin, (i) in the event
that IC exercises its right to enforce the Licensed Patent Rights under Paragraph 11.3, [***] and (ii) in the event that Licensee exercises its right to enforce the Licensed Patent Rights under Paragraph 11.3,
[***]. 

  

	 	11.6	 The IC shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The IC agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The IC offers no warranties other than those specified in Article 1. IC further warrants that to
the best of its knowledge it has not granted and will not grant any licenses or rights to the Licensed Patent Rights within the Licensed Fields of Use of this Agreement. 

 

	 	12.2	 The IC does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of a Third Party.

  

	 	12.3	 THE IC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	 The IC does not represent that it shall commence legal actions against any Third Party infringing
the Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage resulting from a suit or proceeding brought by a Third Party against
any of them to the extent arising out of: 

  

	 	(a)	 the use by or on behalf of the Licensee, its Sublicensees, directors, employees, or Third
Parties of any Licensed Patent Rights in the Licensed Fields of Use; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or
materials by the Licensee, or other products or processes developed in connection with or arising out of Licensee’s practice of the Licensed Patent Rights; 

provided that Licensee’s indemnification obligations shall not apply to the extent such claim results from the negligence, willful
misconduct or breach of this Agreement by the IC, or from the exploitation of Licensed Patent Rights by or under the authority of Additional Licensee(s). 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.
The IC shall provide Licensee with prompt written notice upon becoming aware of any claims that are subject to Licensee’s indemnification obligations under Paragraph 12.5 above, and Licensee shall have the right to
control the defense and settlement of any such claim. The IC shall cooperate with Licensee in such defense or settlement, at Licensee’s reasonable request and expense, and shall not make any admissions in connection with
such claim. 

  

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.17 are not
fulfilled, and shall extend to the expiration of the last to expire Valid Claim within the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 

 

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within [***] after the date of notice in writing of the default, the IC may terminate this Agreement by
written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a Third Party’s intention to file an involuntary petition in bankruptcy, the Licensee shall promptly notify the IC in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the IC [***] written notice to that effect. 

  

	 	13.5	 The IC shall specifically have the right to terminate this Agreement pursuant to Paragraph 13.6,
such termination to be deemed effective upon the earliest of: 1. expiration of the [***] time period by which Licensee can submit a formal written appeal, if such period expires without submission by Licensee of such appeal, 2. upon
final agency decision in response to the formal written appeal in accordance with Paragraph 13.9, or 3. upon Licensee’s written notification of its acceptance of the termination of this Agreement, if the IC
reasonably determines that the Licensee: 

  

	 	(a)	 is not using reasonable commercial efforts to execute the Commercial Development Plan submitted with its
request for a license (as amended in accordance with this Agreement) and the Licensee cannot otherwise demonstrate to the IC’s reasonable satisfaction that the Licensee has taken, or can be expected to take within a
reasonable time, reasonable commercial steps to achieve the Practical Application of the Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not achieved the Benchmarks as may be modified under Paragraph 9.2; 

 

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; 

  

	 	(f)	 cannot reasonably satisfy unmet health and safety needs; 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(g)	 has been found by a court of competent jurisdiction to have violated the Federal antitrust laws in connection
with its performance under this Agreement; or 

  

	 	(h)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived. 

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, the IC shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the IC shall give written notice to the Licensee providing the Licensee specific notice of, and a [***] opportunity to respond to, the IC’s concerns as to the items referenced
in 13.5(a)-13.5(h). If the Licensee fails to alleviate the IC’s concerns as to the items referenced in 13.5(a)-13.5(h) or fails to initiate corrective
action to the IC’s reasonable satisfaction within such [***] period, the IC may terminate this Agreement upon written notice to Licensee. 

 

	 	13.7	 When the public health and safety so require, and after written notice to the Licensee providing the
Licensee a [***] opportunity to respond, the IC shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent
Rights, unless the Licensee can reasonably demonstrate that the granting of the sublicense would not alleviate concerns of public health and safety and materially increase the availability to the public of the subject matter of the
Licensed Patent Rights. The IC shall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with the Licensee. 

 

	 	13.8	 The IC reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this
Agreement upon written notice to Licensee if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not
reasonably satisfied by the Licensee. 

  

	 	13.9	 Within [***] of receipt of written notice of the IC’s unilateral decision to modify or terminate
this Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated IC official or designee. The decision of the designated IC
official or designee shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be accessible. 

 

	 	13.10	 Within [***] of expiration or termination of this Agreement under this Article 13, a final report shall
be submitted by the Licensee to the IC with respect to any royalties due and unpaid. Any royalty payments, including those incurred but not yet paid (such as the execution royalty and full minimum annual royalty), and those related to
patent expenses, due to the IC shall become due and payable upon termination or expiration, together with such report. If terminated under this Article 13, Sublicensees may elect to convert their sublicenses to direct licenses with the
IC pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this Agreement, upon termination (but not expiration) of this Agreement, the Licensee shall return all Licensed Products or other
materials included within the Licensed Patent Rights to the IC or provide the IC with certification of the destruction thereof, within a period of [***] after such termination. The Licensee may not be granted additional
IC licenses if the final reporting requirement is not fulfilled. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of a party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by such party or excuse a similar subsequent failure to perform any of
these terms or conditions by the other party. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings with respect to such subject matter are merged into, extinguished by, and
completely expressed by this Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 Upon receipt by the IC of the license issue royalty and the prorated first year minimum annual royalty
and verification of these royalties, the IC agrees to transfer the Licensed Materials to the Licensee, as available, or authorize the transfer of Licensed Materials to Licensee by a Third Party, and
to replace these Licensed Materials, as available, at reasonable cost, in the event of their unintentional destruction. Within [***] of the termination or expiration of this Agreement, the Licensee agrees to return all
Licensed Materials and the Licensed Products to the IC or provide the IC with written certification of their destruction. 

  

	 	14.7	 All Agreement notices required or permitted by this Agreement shall be given by prepaid, first
class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be
designated in writing by the other party. Agreement notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark
or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as
proof of timely mailing. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	14.8	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except, by Licensee, to the Licensee’s Affiliate(s) without the prior written
consent of the IC, which shall not be unreasonably withheld, delayed, or conditioned; provided that if the IC does not provide a response within [***] of its receiving such notice of assignment, then the IC is deemed to have
consented to such assignment. The parties agree that the identity of the parties is material to the formation of this Agreement. In the event that the IC approves a proposed assignment, the Licensee shall pay the
IC, as an additional royalty, [***] of the Fair Market Value of any consideration received for any assignment of this Agreement within [***] of the assignment. For clarity, if consideration is received for an assignment of this
Agreement and for the sale or transfer of other assets, Licensee shall fairly and in good faith allocate such consideration among all such assets, and the payment to the IC will be based on the allocation to this
Agreement. 

  

	 	14.9	 The Licensee agrees in its use of any IC-supplied
materials to comply with all applicable statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical
trials in the United States without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States
without notifying the IC, in writing, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the IC of research involving human subjects or
clinical trials outside of the United States shall be given no later than [***] prior to commencement of the research or trials. 

  

	 	14.10	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of
these items may require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The
IC neither represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.11	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve the
IC’s patent rights in those countries. This Paragraph 14.11 shall apply to the extent required by applicable law. 

  

	 	14.12	 By entering into this Agreement, the IC does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
IC, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the IC, the FDA or the HHS or the Government or their employees
in any advertising, promotional, or sales literature without the prior written approval of the IC. 

  

	 	14.13	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	14.14	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the
source of the grant. 

  

	 	14.15	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the IC. 

  

	 	14.16	 Paragraphs 4.3, 8.1, 9.5-9.8,
12.1-12.6, 13.9, 13.10, 14.13 and 14.16 of this Agreement shall survive termination of this Agreement. 

 

	 	14.17	 The terms and conditions of this Agreement shall, at the IC’s sole option, be considered by
the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed
by the Licensee and a fully executed original is received by the IC within [***] from the date of the IC’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 NIH PATENT LICENSE AGREEMENT – EXCLUSIVE

 SIGNATURE PAGE 
  

			
	For the IC:	 	
		
	/s/ Richare U. Rodrigues                    	 	10/30/2020        
	Richard U. Rodriguez, MBA	 	Date

 Associate Director 
 Technology
Transfer Center 
 National Cancer Institute 
 National
Institutes of Health 
 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: [***] 
 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that
the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
 by: 

 

			
	 /s/ Robert Ang
	  	10/30/2020        
	Signature of Authorized Official	  	Date
		
	 Robert Ang
	  	
	Printed Name	  	
		
	 Chief Executive Officer
	  	
	Title	  	

  

							
	        	 	 I.   Official and Mailing Address for Agreement
notices:

				
		 		 	 Amy Mendel
	  	
		 		 	Name	  	
				
		 	    	 	 Chief Legal Officer
	  	
		 		 	Title	  	
				
		 		 	Mailing Address:	  	
		 		 	 Vor Biopharma
 100 Cambridgepark Dr, Suite
400
	  	
		 		 	Cambridge, Massachusetts 02140	  	

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	
	 Email Address: [***]

	
	 Phone:
              617-655-6580

	
	 II. Official and Mailing Address for Financial notices (the Licensee’s contact
person for royalty payments)

	
	 Amy
Quinlan                                        
            

	 Name

	
	 VP,
Finance                                        
              

	 Title

	
	 Mailing Address:

	
	 Vor Biopharma

	 100 Cambridgepark Dr, Suite 400

	 Cambridge, Massachusetts 02140

	
	 Email          Address: [***]

	
	
Phone:        
617-655-6580

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C.
§1001 (criminal liability including fine(s) or imprisonment). 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 

[***] 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	 Licensed Fields of Use: 

The development of a chimeric antigen receptor (CAR) therapy mono-specific for CD33 for the prophylaxis or treatment of CD33-expressing
hematological malignancies wherein the CAR is comprised of the CD33-binding domain referenced as Hu195 or hP67.6, is delivered via lentiviral transduction, and the T cells are: 

1. derived autologously (meaning cells derived from one individual who is both the donor and the recipient) in the first-line or
relapsed/refractory setting, or 
 2. derived allogeneically (meaning cells derived from a matched healthy donor), in the post-transplant
setting 
 For clarity, specifically excluded from this field of use are “CD33-specific logic-gated
CAR-based immunotherapies”, which means therapies where the CAR-expressing T cells recognize CD33 (via the Hu195 or hP67.6 binding domains) and are engineered to
respond to one or more additional antigens (but not necessarily all of the signals). 
  

	II.	 Licensed Territory: 

Worldwide 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX C – ROYALTIES 

Royalties: 
  

	I.	 The Licensee agrees to pay to the IC a noncreditable, nonrefundable license issue royalty in the
amount of four hundred thousand dollars ($400,000), payable as follows: (a) three hundred twenty thousand dollars ($320,000) due within sixty (60) days from the effective date of this Agreement, and (b) eighty thousand dollars
($80,000) due at the first to occur of: 1. the eight month anniversary of the effective date of this Agreement, or 2. termination of this Agreement. 

 

	II.	 The Licensee agrees to pay to the IC a nonrefundable minimum annual royalty in the amount of
twenty five thousand dollars ($25,000) as follows: 

  

	 	(a)	 The first minimum annual royalty is due within [***] days of January 1, 2022; and 

 

	 	(b)	 Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may
be credited against any earned royalties due for sales made in that year. 

  

	III.	 After its receipt of necessary approvals to market and sell the Licensed Product or Licensed
Process, the Licensee agrees to pay the IC the earned royalties, subject to Paragraph 6.6, on Net Sales by or on behalf of the Licensee and its Sublicensees during the applicable Royalty Term, as
follows: 

  

	 	(a)	 Vor Allo Product 

 

	 	(1)	 [***] for that portion of annual aggregate Net Sales of Vor Allo Products less than [***]

  

	 	(2)	 [***] for that portion of annual aggregate Net Sales of Vor Allo Products equal to [***] and up
to [***] 

  

	 	(3)	 [***] for that portion of annual aggregate Net Sales of Vor Allo Products greater than [***]

  

	 	(b)	 IC Auto Product 

 

	 	(1)	 [***] for that portion of annual aggregate Net Sales of IC Auto Products up to [***]

  

	 	(2)	 [***] for that portion of annual aggregate Net Sales of IC Auto Products greater than [***]

  

	 	(c)	 The Licensee shall be entitled to a credit of [***] of any amounts owed to non-Affiliate Third
Parties with respect to Licensed Products in consideration for licenses under intellectual property owned or controlled by such Third Party; provided that such credit shall not reduce the earned royalty due to IC for
Licensed Products and Licensed Processes by more [***] of the amounts otherwise owed, or below a final adjusted royalty rate of [***] on the annual aggregate Net Sales, whichever earned royalty rate is greater.

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 

	 	(d)	 For purposes of the foregoing, the “Royalty Term” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, the period commencing on the First Commercial Sale of such Licensed Product in such
country until the expiration of the last Valid Claim covering such Licensed Product in such country. 

  

	IV.	 The Licensee agrees to pay the IC one-time
Benchmark royalties within [***] of achieving the first occurrence of a Benchmark with respect to a Licensed Product by Licensee: 

  

	 	(a)	 [***] upon [***] 

  

	 	(b)	 [***] upon [***] 

  

	 	(c)	 [***] upon [***] 

  

	 	(d)	 [***] upon [***] 

  

	 	(e)	 [***] upon [***]  

 

	 	(f)	 [***] upon [***] 

  

	 	(g)	 [***] upon [***] 

  

	 	(h)	 [***] upon [***] 

  

	 	(i)	 [***] when the aggregate Net Sales of all Licensed Products reaches [***] 

 

	 	(j)	 [***] when the aggregate Net Sales of all Licensed Products reaches [***] 

 

	 	(k)	 [***] when the aggregate Net Sales of all Licensed Products reaches [***] 

With respect to Benchmarks (a) through (c), if a Benchmark is skipped (each a “Skipped Benchmark”) so that
a subsequent Benchmark within a given regulatory pathway for a Licensed Product is achieved prior to one or more Skipped Benchmarks of an earlier stage, then payments corresponding to such Skipped Benchmarks shall be
deemed due and payable within [***] of the achievement of a subsequent Benchmark (so long as such subsequent Benchmark is not also a Skipped Benchmark). 
  

	V.	 The Licensee agrees to pay the IC additional sublicensing royalties equal to the applicable
percentage (as set forth below) of any Sublicensing Revenue received for granting each sublicense within [***] of Licensee’s receipt of such Sublicensing Revenue. For any sublicense agreement, the applicable percentage owed
by Licensee on Sublicensing Revenue will be determined by the date on which the sublicense was granted: 

  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; and 

[***].      

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX D – BENCHMARKS AND PERFORMANCE 

The Licensee agrees to the following Benchmarks for its performance under this Agreement and, within [***] of achieving a
Benchmark, shall notify the IC that the Benchmark has been achieved. 
  

	I.	 [***] 

  

	II.	 [***] 

  

	III.	 [***] 

  

	IV.	 [***] 

  

	V.	 [***] 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

[***] 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX F – EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	 	•	 	 License reference number
(L-XXX-200X/0) 

  

	 	•	 	 Reporting period 

  

	 	•	 	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	 	•	 	 Gross Sales per catalog number per country 

 

	 	•	 	 Total Gross Sales 

  

	 	•	 	 Itemized deductions from Gross Sales 

 

	 	•	 	 Total Net Sales 

  

	 	•	 	 Earned Royalty Rate and associated calculations 

 

	 	•	 	 Gross Earned Royalty 

  

	 	•	 	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	 	•	 	 Net Earned Royalty due 

Example 
  

									
	 Catalog Number
	 	 Product Name
	 	 Country
	 	 Units Sold
	 	 Gross Sales (US$)

	 1
	 	A	 	US	 	250	 	62,500
	 1
	 	A	 	UK	 	32	 	16,500
	 1
	 	A	 	France	 	25	 	15,625
	 2
	 	B	 	US	 	0	 	0
	 3
	 	C	 	US	 	57	 	57,125
	 4
	 	D	 	US	 	12	 	1,500

  

							
		  	 Total Gross Sales
	  	 	153,250	 
		  	Less Deductions:	  			
		  	 Freight
	  	 	3,000	 
		  	 Returns
	  	 	7,000	 
		  	 Total Net Sales
	  	 	143,250	 
		  	 Royalty Rate
	  	 	8	% 
		  	 Royalty Due
	  	 	11,460	 
		  	Less Creditable Payments	  	 	10,000	 
		  	 Net Royalty Due
	  	 	1,460	 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 APPENDIX G – ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S.
Treasury web site located at: https://www.pay.gov/public/form/start/28680443. 
 Automated Clearing House (ACH) for payments through
U.S. banks only 
 The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit
your ACH payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443. Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site. 

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via
Electronic Funds Wire Transfer sender MUST supply the following information within the transmission: 
 Drawn on a U.S. bank account via FEDWIRE:

 Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND.

 [***] 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 Agency Contacts:    Office of Technology Transfer
(OTT)    [***] 
 Drawn on a foreign bank account via FEDWIRE: 

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD). 

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable. 

[***] 

 Portions of this agreement (indicated by “[***]”) have been omitted as the
Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. 

 
 Agency Contacts: 

Office of Technology Transfer         (OTT)        [***] 

Checks 
 All checks should be made payable to
“NIH Patent Licensing” 
 Checks drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following
address: 
 National Institutes of Health 

P.O. Box 979071 
 St. Louis, MO
63197-9000 
 Checks drawn on a U.S. bank account and sent by overnight or courier should be sent to the following address: 

US Bank 
 Government Lockbox SL-MO-C2GL 
 1005 Convention Plaza 

St. Louis, MO 63101 
 Phone: 314-418-4087 
 Checks drawn on a foreign bank account should be
sent directly to the following address: 
 National Institutes of Health 

Office of Technology Transfer 

License Compliance and Administration 

Royalty Administration 
 6011
Executive Boulevard 
 Suite 325, MSC 7660 

Rockville, Maryland 20852

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]